ID

44287

Descrição

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02392039

Link

https://clinicaltrials.gov/show/NCT02392039

Palavras-chave

  1. 30/04/2019 30/04/2019 -
  2. 30/04/2019 30/04/2019 -
  3. 20/09/2021 20/09/2021 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

20 de setembro de 2021

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Lymphoma NCT02392039

Eligibility Lymphoma NCT02392039

  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT02392039
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients must have newly diagnosed, previously untreated diffuse large b-cell lymphoma, mantle cell lymphoma, grade 3b follicular lymphoma, burkitt lymphoma, peripheral t cell lymphoma nos, nk/t cell lymphoma, or transformed lymphoma.
Descrição

Diffuse Large B-Cell Lymphoma Untreated | Mantle cell lymphoma Untreated | Follicular Lymphoma Grade Untreated | Burkitt Lymphoma Untreated | Peripheral T-Cell Lymphoma Untreated | NK/T-cell lymphoma Untreated | Lymphoma transformation Untreated

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0334634
UMLS CUI [2,2]
C0332155
UMLS CUI [3,1]
C0024301
UMLS CUI [3,2]
C0441800
UMLS CUI [3,3]
C0332155
UMLS CUI [4,1]
C0006413
UMLS CUI [4,2]
C0332155
UMLS CUI [5,1]
C0079774
UMLS CUI [5,2]
C0332155
UMLS CUI [6,1]
C0558916
UMLS CUI [6,2]
C0332155
UMLS CUI [7,1]
C0024299
UMLS CUI [7,2]
C0040682
UMLS CUI [7,3]
C0332155
2. planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to r-chop, r-epoch, and r-hypercvad, chop, and smile.
Descrição

Chemotherapy cycle Quantity Planned | pegfilgrastim | Risk Febrile Neutropenia Diminishing | R-CHOP chemotherapy regimen | R-EPOCH Regimen | Other Coding | CHOP regimen | Other Coding

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1302181
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C1301732
UMLS CUI [2]
C1136535
UMLS CUI [3,1]
C0035647
UMLS CUI [3,2]
C0746883
UMLS CUI [3,3]
C0205216
UMLS CUI [4]
C4302501
UMLS CUI [5]
C1882521
UMLS CUI [6]
C3846158
UMLS CUI [7]
C0163868
UMLS CUI [8]
C3846158
3. age >= 18 years old.
Descrição

Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
4. ecog performance status 0-3.
Descrição

ECOG performance status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
5. ability to provide informed consent for participation.
Descrição

Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. existing chronic bone pain prior to pegfilgrastim usage.
Descrição

Bone pain chronic | Status pre- Use of Pegfilgrastim

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0151825
UMLS CUI [1,2]
C0205191
UMLS CUI [2,1]
C0332152
UMLS CUI [2,2]
C1524063
UMLS CUI [2,3]
C1136535
2. creatinine clearance of <50ml/minute by cockcroft gault equation.
Descrição

Estimation of creatinine clearance by Cockcroft-Gault formula

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2711451
3. allergy to filgrastim, pegfilgrastim, or loratadine.
Descrição

Filgrastim allergy | Hypersensitivity Pegfilgrastim | Loratadine allergy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0570660
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1136535
UMLS CUI [3]
C0571031
4. chronic daily usage of antihistamine without an acceptable alternative non-antihistamine medication.
Descrição

Antihistamines Used daily chronic | Pharmaceutical Preparations Alternative Lacking

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0019590
UMLS CUI [1,2]
C3845591
UMLS CUI [1,3]
C0205191
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1523987
UMLS CUI [2,3]
C0332268
5. inability to swallow medications.
Descrição

Lacking Able to swallow Oral medication

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C2712086
UMLS CUI [1,3]
C0175795
6. inability to complete the survey instrumentation accurately.
Descrição

Survey Completion Unable

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0038951
UMLS CUI [1,2]
C0205197
UMLS CUI [1,3]
C1299582

Similar models

Eligibility Lymphoma NCT02392039

  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT02392039
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Diffuse Large B-Cell Lymphoma Untreated | Mantle cell lymphoma Untreated | Follicular Lymphoma Grade Untreated | Burkitt Lymphoma Untreated | Peripheral T-Cell Lymphoma Untreated | NK/T-cell lymphoma Untreated | Lymphoma transformation Untreated
Item
1. patients must have newly diagnosed, previously untreated diffuse large b-cell lymphoma, mantle cell lymphoma, grade 3b follicular lymphoma, burkitt lymphoma, peripheral t cell lymphoma nos, nk/t cell lymphoma, or transformed lymphoma.
boolean
C0079744 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0334634 (UMLS CUI [2,1])
C0332155 (UMLS CUI [2,2])
C0024301 (UMLS CUI [3,1])
C0441800 (UMLS CUI [3,2])
C0332155 (UMLS CUI [3,3])
C0006413 (UMLS CUI [4,1])
C0332155 (UMLS CUI [4,2])
C0079774 (UMLS CUI [5,1])
C0332155 (UMLS CUI [5,2])
C0558916 (UMLS CUI [6,1])
C0332155 (UMLS CUI [6,2])
C0024299 (UMLS CUI [7,1])
C0040682 (UMLS CUI [7,2])
C0332155 (UMLS CUI [7,3])
Chemotherapy cycle Quantity Planned | pegfilgrastim | Risk Febrile Neutropenia Diminishing | R-CHOP chemotherapy regimen | R-EPOCH Regimen | Other Coding | CHOP regimen | Other Coding
Item
2. planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to r-chop, r-epoch, and r-hypercvad, chop, and smile.
boolean
C1302181 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
C1136535 (UMLS CUI [2])
C0035647 (UMLS CUI [3,1])
C0746883 (UMLS CUI [3,2])
C0205216 (UMLS CUI [3,3])
C4302501 (UMLS CUI [4])
C1882521 (UMLS CUI [5])
C3846158 (UMLS CUI [6])
C0163868 (UMLS CUI [7])
C3846158 (UMLS CUI [8])
Age
Item
3. age >= 18 years old.
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
4. ecog performance status 0-3.
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
5. ability to provide informed consent for participation.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Bone pain chronic | Status pre- Use of Pegfilgrastim
Item
1. existing chronic bone pain prior to pegfilgrastim usage.
boolean
C0151825 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0332152 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
C1136535 (UMLS CUI [2,3])
Estimation of creatinine clearance by Cockcroft-Gault formula
Item
2. creatinine clearance of <50ml/minute by cockcroft gault equation.
boolean
C2711451 (UMLS CUI [1])
Filgrastim allergy | Hypersensitivity Pegfilgrastim | Loratadine allergy
Item
3. allergy to filgrastim, pegfilgrastim, or loratadine.
boolean
C0570660 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C1136535 (UMLS CUI [2,2])
C0571031 (UMLS CUI [3])
Antihistamines Used daily chronic | Pharmaceutical Preparations Alternative Lacking
Item
4. chronic daily usage of antihistamine without an acceptable alternative non-antihistamine medication.
boolean
C0019590 (UMLS CUI [1,1])
C3845591 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C1523987 (UMLS CUI [2,2])
C0332268 (UMLS CUI [2,3])
Lacking Able to swallow Oral medication
Item
5. inability to swallow medications.
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0175795 (UMLS CUI [1,3])
Survey Completion Unable
Item
6. inability to complete the survey instrumentation accurately.
boolean
C0038951 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial